Figure 5.
BRD4 binding enhances IL-15 receptor complex expression in CTCL patient cells. (A) Gene tracks depicting genomic occupancy of BRD4 (rpm per bp) at regulatory regions of IL-15 receptor complex loci in CD4+ T cells from a normal donor, a CTCL patient, and patient cells treated with 100 nM JQ1 for 24 hours in vitro. (B) Immunoblot of IL-15 receptor complex subunits (α, β, and γ) in HuT-102 cell line treated with vehicle or 1 µM JQ1 for 48 hours, with actin as internal control. (C) Immunoblot of BRD4 and IL-15 receptor complex in HuT-102 cells treated in vitro with vehicle or 50 nM bortezomib for 24 hours with actin as internal control. (D) Immunoblot of IL-15 receptor constituent protein expression in splenocytes from miR-29b−/− mice and age-matched WT mice (n = 4 each). Data are presented as mean ± SEM unless otherwise specified.

BRD4 binding enhances IL-15 receptor complex expression in CTCL patient cells. (A) Gene tracks depicting genomic occupancy of BRD4 (rpm per bp) at regulatory regions of IL-15 receptor complex loci in CD4+ T cells from a normal donor, a CTCL patient, and patient cells treated with 100 nM JQ1 for 24 hours in vitro. (B) Immunoblot of IL-15 receptor complex subunits (α, β, and γ) in HuT-102 cell line treated with vehicle or 1 µM JQ1 for 48 hours, with actin as internal control. (C) Immunoblot of BRD4 and IL-15 receptor complex in HuT-102 cells treated in vitro with vehicle or 50 nM bortezomib for 24 hours with actin as internal control. (D) Immunoblot of IL-15 receptor constituent protein expression in splenocytes from miR-29b−/− mice and age-matched WT mice (n = 4 each). Data are presented as mean ± SEM unless otherwise specified.

Close Modal

or Create an Account

Close Modal
Close Modal